Burning Rock BiotechFRA:6BU0 -6.16%56 Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus rates FRA:6BU0 with a GF Score™ of 56/100 and a GF Value™ of €5.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 61 Medical Diagnostics & Research companies, Burning Rock Biotech ranks worse than 1639342.62% on this metric.
As of today (2026-07-01), the Forward Annual Dividend Yield of Burning Rock Biotech is 0.00%.
As of today (2026-07-01), the Trailing Annual Dividend Yield of Burning Rock Biotech is 0.00%.
FRA:6BU0's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.86 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Burning Rock Biotech (FRA:6BU0) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Burning Rock Biotech Forward Dividend Yield % Related Terms
FRA:6BU0 vs XGN, IDXG, PRPO: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Burning Rock Biotech (FRA:6BU0) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry.
Is Burning Rock Biotech's Forward Dividend Yield % too high?
Burning Rock Biotech's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Burning Rock Biotech ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Forward Dividend Yield % compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #999999 out of 61 companies for Forward Dividend Yield %. This places Burning Rock Biotech in the lower half of its industry. The industry median Forward Dividend Yield % is 1.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.86, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.99, compared to a current price of €6.85 — trading 14.4% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Burning Rock Biotech's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €6.85 is trading 14.4% above its estimated GF Value™ of €5.99.
GuruFocus considers Burning Rock Biotech to be Modestly Undervalued.
Key valuation signals for FRA:6BU0:
Forward Dividend Yield %: 0.00%
GF Value™: €5.99 vs. price of €6.85 (14.4% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
56GF Score
Get the complete analysis for FRA:6BU0
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 